Stellar Biotechnologies shares jump on vax deal; Morning shots could be better for men;

> Stellar Biotechnologies has licensed-in rights to C. difficile vaccine technology and saw its shares jump by a third. Press release | Article

> A group of institutions in San Antonio is launching the San Antonio Vaccine Development Center. Article

> Nuron Biotech has licensed Vitruvian BioMedical's DNA vaccine against amyloid beta 42 for the treatment of Alzheimer's disease. Press release

> GlaxoSmithKline's ($GSK) malaria vaccine, RTS,S (Mosquirix), is showing efficacy in Rwanda and other African countries. News

> The Vietnamese Ministry of Health is conducting Phase III trials of an H5N1 vaccine in 1,000 healthy volunteers. Item

> Keeping babies warm during jabs is the best pain relief. Report

> Changing the timing of jabs could improve immunity; a study has suggested immunizing men in the morning and women in the afternoon. Article

> HIV researchers get $2.7 million to develop HIV vaccines. Press release

And Finally… Vaccine developer Mymetics has appointed Grant Pickering as president and CEO and Christopher Henney as chair of the board of directors. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.